The protocol at a glance
There is no label and no trial, so there is no schedule to report.
| Item | What the sources show |
|---|---|
| Human dose | Not established |
| Studied in | No published studies found |
Searches of PubMed and ClinicalTrials.gov on 5 Nov 2026 found no Adamax peptide papers or trials. The only PubMed hit for "Adamax peptide" was an unrelated computing paper. Seller pages disagree on the exact structure.
Community notes report 200 to 600 mcg a day for 4 to 8 weeks. That looks borrowed from Semax ranges, not from Adamax data.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing
No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.
What the trials found
There are no results to show. What the searches found:
Searches run 5 Nov 2026. Semax findings do not transfer to Adamax.
Side effects
- No safety data exists for Adamax.
- Do not assume Semax's label safety list applies to it.
How it works
Unknown
Sellers say an added adamantane group helps it reach the brain and last longer. No study backs this.
Sources
- PubMed search by name, run 5 Nov 2026: no relevant results for Adamax peptide
- ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results
- Seller listings (peptide-db.com, peptide-assistant.vercel.app), used only to show their claims conflict; not scientific sources
- RLS (rlsnet.ru) Semax entry (the parent drug)